Heme/onc/geriatrician @UNMC @NebraskaMedicine studying Myeloma & other cancers + Aging. Training for Peru Trek: https://t.co/wI3oswKkxL
Sep 23, 2020 • 12 tweets • 5 min read
I have done the academically unfathomable:
I am resigning my faculty position without another job lined up. While I am 100% confident in my decision, I am also 100% sad.
This did not have to happen. #womeninmedicine 1/
I am not burned out. I love what I do. I love my patients and I love my research. I am not quitting my calling. I am being brave enough to be CEO of my own life. @RUBraveEnough 2/
Dec 9, 2019 • 5 tweets • 3 min read
Abs 694: Dr Puiz presents GEM-Claridex trial of Rd vs Clarithromycin-RD. Got to witness Sweet moment at end when her mentor @mvmateos flashed her the “Great job, my protege!” smile we all need to see ❤️
GEM-Clarieex provides another cautionary tale about a myeloma regimen that is more effective but more toxic in older patients #geriheme....
Dec 8, 2019 • 6 tweets • 4 min read
Blown away by rising star @mwschoen's masterful storytelling of how he is trying to understand and eradicate racial disparities in myeloma treatment and outcomes...
file:///var/folders/mw/0w9f93f97wscrp764dmz0k900000gp/T/com.apple.iChat/Messages/Transfers/IMG_6462.jpeg #ASH19@mwschoen Dr. Schoen walks us through a hypothesis that renal impairment and racial differences in estimating renal function may impact treatment and outcome: 1) Pts with renal dies less likely to receive lenalidomide.
Abs 268: @HiraSMian presents data on >5700 pts with MM from Canadian registry with some good/some sobering news for #geriheme pts: 1. ASCT use rising 2. 60% of older pts get a novel drug 3. 20% 1-yr mortality 4. 30% of older patients received NO MYELOMA TREATMENT #ASH19
Even with universal coverage, older pts, lower SES or more comorbidities less likely to be treated for myeloma #mmsm#geriheme#ASH19
Dec 7, 2019 • 4 tweets • 3 min read
Abstract 67: all new patients with blood cancer age >=75 screened for frailty; participants randomized to receive geriatric consultation. Outcomes: feasibility, 1-yr OS, acute care utilization, goals of care discussion. ash.confex.com/ash/2019/webpr…
86% participated in RCT, but some patients worried that geriatric consultation would make them ineligible for treatment. Just heard this same observation from another #geriheme MD on the opposite side of the country just last night! @ROlinMD